RE:Merck to buy Prometheus Bio....Fox, I share your frustration. Like you I have been invested in this stock for far to long (23 years). The valuation and the retail interest in this stock has always been a concern, especially when they post, what seem to be break throughs on cancers like breast, pancreatic cancer and possibly colon. None of these results have attracted new retail investors nor a partner. Why? Is it because the test results, although seem possitive, were too small a sample size? Or does BP see something else that concerns them? We saw the same scenario play out with the failed H&N PIII trial. Leading up to this trial reo seemed to be the answer to this disease and then the design was flawed and conclusions were left with more questions than answers. Obviously we the retailer are not privy to the thinking of the BP and why they have not made the commitment to partner or buyout. It would be nice to know for certain the reason for this but one can only conclude that they don't think it works. Hard to accept we have been duped all these years but if nothing happens by June it would seem this realization must be accepted.